South Korean researchers led by Lee In-suk of Yonsei University have reported the most complete oral microbiome catalog to date, with more than 72,000 genomes. Detailed in Cell Host & Microbe on Nov. 12, 2025, the database is expected to serve as a universal platform for academia and enable “precision microbiome medicine” for the industry, Lee told BioWorld.Read More
Gentibio Inc. has developed and presented data for GNTI-823, an allogeneic tissue Treg engineered from peripheral blood CD4+ T cells with CRISPR-based editing to induce FOXP3 expression, a rapamycin-inducible IL-2 signaling complex and an alarmin-responsive transgene. Read More
Sutro Biopharma Inc. has outlined its next-generation antibody-drug conjugate (ADC) pipeline following recent IND clearance and initiation of phase I for its tissue factor-targeting ADC, STRO-004. Read More
Korro Bio Inc. has nominated KRRO-121 as its next development candidate, for the treatment of patients with hyperammonemia, including patients with urea cycle disorders and hepatic encephalopathy. Read More
Investigators from the University of Science and Technology of China and RNAlfa Biotech have described a novel mRNA-based vaccine candidate against Dabie Banda virus (DBV), which has fatality rates of up to 30% in some East Asian countries.
Read More
Editor Annette Boyle discusses the challenges med-tech companies face in bringing innovation to market and how the industry can overcome them. Read More
Innovstone Therapeutics Ltd. has disclosed integrin αLβ2 (LFA-1)/ICAM-1 interaction inhibitors and/or RASP-trapping agents reported to be useful for the treatment of dry eye syndrome. Read More
Pinotbio Inc. recently reported a novel antibody-drug conjugate (ADC), named PBX-004, consisting of an ITGB6-targeting antibody conjugated to a potent topoisomerase I (TOP1) inhibitor payload. Read More
Researchers at 35pharma Inc. have recently presented data for the activin receptor inhibitor HS-235, which is under development for the treatment of obesity as it exerts body composition and metabolism control. Read More
3H Pharmaceuticals Co. Ltd. has synthesized Werner syndrome ATP-dependent helicase (WRN; RECQ3; RECQL2) inhibitors reported to be useful for the treatment of cancer. Read More
Two attractive drug targets in tumors are carbonic anhydrase IX (CAIX), which helps maintain pH homeostasis in the hypoxic tumor, and glutathione peroxidase 4 (GPX4), which can reduce oxidative stress. Researchers from Università degli Studi di Firenze and collaborators aimed to inhibit both CAIX and GPX4 simultaneously. Read More
Hangzhou Synrx Therapeutics Technology Co. Ltd. has divulged crystalline salts of DNA polymerase θ (POLθ) inhibitors reported to be useful for the treatment of cancer. Read More
Suzhou Junjian Yifang Biopharmaceutical Co. Ltd. has described pyrimido[6,1-a]isoquinolin-4-one derivatives acting as dual phosphodiesterase PDE3 and PDE4 inhibitors reported to be useful for the treatment of asthma and chronic obstructive pulmonary disease. Read More
CIS Biopharma AG recently presented an antibody-drug conjugate (ADC) targeting the L1 cell adhesion molecule (L1CAM/CD171) as a potential candidate for the treatment of advanced tumors. Read More
This reoccurring series features new molecular entities (NMEs) revealed for the first time in current literature, at congresses and in company communications during the quarter. Click "read more" to see a list of past reports that are available to BioWorld Science and BioWorld Premuim subscribers. Read More
